title: Primary malignant lymphoma of the intestine.
abstract: Primary intestinal lymphoma is uncommon but not rare. Its pathology and potential therapy are complex. Its epidemiology has changed radically over the past century, reflecting a sharp surge in the incidence of intestinal lymphoma, particularly that associated with immunosuppression. Recent advances in diagnosis, a new approach to pathologic classification by immunotyping, and a new staging system have influenced therapy. New multimodal therapeutic protocols have improved the prognosis of this once deadly disease.
authors.affiliation: Department of Surgery, Yale University School of Medicine, New Haven, Connecticut 06520-8062.
authors.forename: G A
authors.initials: GA
authors.lastname: Turowski
authors.forename: M D
authors.initials: MD
authors.lastname: Basson
mesh_terms: D002985:Clinical Protocols; D003131:Combined Modality Therapy; D006801:Humans; D016130:Immunophenotyping; D007414:Intestinal Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D008223:Lymphoma / Q000175:diagnosis / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012307:Risk Factors; D014481:United States / Q000453:epidemiology